alexa The Effect of MicroRNAs on Cancer Cell | OMICS International
ISSN: 1747-0862
Journal of Molecular and Genetic Medicine
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

The Effect of MicroRNAs on Cancer Cell

Tantawy M*

Department of Cancer, Children's Cancer Hospital, Egypt

*Corresponding Author:
Marwa Tantawy
Department of Cancer
Children's Cancer Hospital, Egypt
Tel: 20225351500
E-mail: [email protected]

Received Date: January 19, 2017; Accepted Date: February 03, 2017; Published Date: February 06, 2017

Citation: Tantawy M (2017) The Effect of MicroRNAs on Cancer Cell. J Mol Genet Med 11:242 doi: 10.4172/1747-0862.1000242

Copyright: © 2017 Tantawy M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Visit for more related articles at Journal of Molecular and Genetic Medicine

Introduction

MicroRNAs (miRNAs) are small single-stranded noncoding RNA of about 20–25 nucleotides in length. Since finding in the early 1990s in C. elegans [1], these small molecules have an important role in the regulation of a wide range of biological processes, as regulation of gene expression and control many pathways as cell growth, differentiation, and apoptosis by controlling their target gene expression. The miRNAs have negative regulation of gene expression by binding 3’ untranslated regions of mRNA of a protein-coding gene, producing a degradation or blockage of translation of these mRNAs [2]. One of the most recent discoveries in molecular oncology over the last decade is the interaction between abnormalities in protein-coding genes and miRNAs that are causally involved in cancer initiation, progression, and metastasis. In recent years, more data have described the active participation of miRNAs in regulating gene expression is produced by microenvironment cells [3].

Mature miRNAs reduce the stability of mRNA including; the genes mediate processes in tumorigenesis, such as cell cycle regulation, inflammation, stress response, differentiation, invasion, and apoptosis. MiRNA targeting accomplished through specific base-pairing interactions between the 5´ end of the miRNA and sites in coding and untranslated regions (UTRs) of mRNAs; target locations in the 3 UTR result in more active mRNA destabilization. From the previous studies, it became apparent that alterations in the expression of miRNA contribute to the pathogenesis of most human malignancies as; miR- 15a/miR-16-1 downregulated in chronic lymphocytic lymphoma [4], miR-21 act as a potential biomarker to identify metastatic gastric cancer with chemo-resistance [5], miR-155 in colon [6], and hepatocellular carcinoma (HCC) diseases [7], miR-200 in colon cancer [8], miR-210 correlated with outcome of prostate cancer [9], miR-221 as a prognostic biomarker for the recurrence in papillary thyroid cancer [10], miR-320 was downregulated in non-small cell lung cancer [11], etc., have been found to be differentially expressed in various tumor tissues and cancer cells as (HCC), breast cancer. And accordingly their differential roles in carcinogenesis, they are categorized as either oncogenes or tumor suppressors [12].

Recently, microarray analysis has declared that a subset of miRNA are up and downregulated during the development of HCC [13]. Reductions in the expression of miRNAs acting as tumor suppressor genes are frequently observed in HCC, and the targets of these downregulated miRNAs may be putative oncogenes. On the other hand, some of the upregulated miRNAs act as oncogenic miRNA in HCC and may be targets of tumor suppressor genes [14].

Earlier studies indicated specific changes in miRNA expression patterns in HCC as compared with normal liver tissue adjacent to tumor tissues, or liver cirrhosis which correlated with the disease outcome [15,16].

Previous studies found, the expression of 188 different miRNAs in HCC patients and adjacent normal liver tissues obtained from 12 hepatitis B virus (HBV) positive and 14 hepatitis c virus (HCV) positive patients, the expression of six miRNAs was decreased in HBV patients, and that of 13 miRNAs was decreased in HCV patients. These data suggested that there are different patterns in the miRNA profiles between HBV and HCV infection associated with HCC patients [14,17].

Earlier studies reported that miRNAs have a critical role in key pathways, which makes them useful candidates as biomarkers for cancer diagnosis and prognosis of paediatric brain tumours. In addition, their stability in bodily fluids, function in several tissues, and their capability to detect early phase disease are useful attributes [1820]. The different treatments currently used, such as radiotherapy and chemotherapy, play an essential role in improving outcomes, but finding biomarkers for better diagnosis, prognosis, and the management of disease progression is necessary [21,22].

A previous study identified miR-29 as a negative regulator of the B7-H3 protein, which acts as a surface immunomodulatory glycoprotein inhibiting natural killer (NK) and T-cell functions [23]. A previous study showed an inverse correlation between miR-29 and B7- H3 in solid tumours in cell line experiments [24]; in addition this study showed the role of miR-29 in the promotion of anti-tumour immunity mediated by NK and T-cells [25].

Conclusion

The advancement of new sensitive detection technologies as qRTPCR, microarray, and deep sequencing has found distinct miRNA expression profile in serum/plasma, urine, and saliva, as well as seminal, amniotic, and pleural effusions from patients with cancer. These circulating miRNAs can play an essential role in the prediction of chemotherapeutic response; in addition, their diagnostic or prognostic value [26]. So miRNAs act as promising therapeutic agents and several pharmaceutical companies already have miRNA therapeutics in their developmental pipeline [3].

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 625
  • [From(publication date):
    March-2017 - Dec 18, 2017]
  • Breakdown by view type
  • HTML page views : 554
  • PDF downloads : 71
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version